treatment development

Explore the groundbreaking Radioligand Program developed by Dana-Farber Cancer Institute and Gustave Roussy, aimed at revolutionizing cancer treatment. This initiative focuses on the application of radioligands for targeted therapy, improving patient outcomes with reduced side effects. Join experts like Professors Toni Choueiri and Karim Fizazi at the 'Radiopharmaceutical Therapy Meets Oncology' conference to learn about advancements in precision oncology, clinical applications, and the role of collaborative initiatives in cancer care. Stay informed on the latest research and treatments transforming the oncology landscape.